JP2016510340A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510340A5
JP2016510340A5 JP2015557221A JP2015557221A JP2016510340A5 JP 2016510340 A5 JP2016510340 A5 JP 2016510340A5 JP 2015557221 A JP2015557221 A JP 2015557221A JP 2015557221 A JP2015557221 A JP 2015557221A JP 2016510340 A5 JP2016510340 A5 JP 2016510340A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cannabinoids
affinity
tablet
dimethylheptyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015557221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510340A (ja
JP6689078B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/016050 external-priority patent/WO2014127016A2/en
Publication of JP2016510340A publication Critical patent/JP2016510340A/ja
Publication of JP2016510340A5 publication Critical patent/JP2016510340A5/ja
Application granted granted Critical
Publication of JP6689078B2 publication Critical patent/JP6689078B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015557221A 2013-02-12 2014-02-12 超高純度なテトラヒドロカンナビノール−11−酸 Expired - Fee Related JP6689078B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361763630P 2013-02-12 2013-02-12
US61/763,630 2013-02-12
US201361837743P 2013-06-21 2013-06-21
US61/837,743 2013-06-21
PCT/US2014/016050 WO2014127016A2 (en) 2013-02-12 2014-02-12 Ultrapure tetrahydrocannabinol-11-oic acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018178162A Division JP2019031505A (ja) 2013-02-12 2018-09-22 超高純度なテトラヒドロカンナビノール−11−酸

Publications (3)

Publication Number Publication Date
JP2016510340A JP2016510340A (ja) 2016-04-07
JP2016510340A5 true JP2016510340A5 (enExample) 2017-03-16
JP6689078B2 JP6689078B2 (ja) 2020-04-28

Family

ID=51354671

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015557221A Expired - Fee Related JP6689078B2 (ja) 2013-02-12 2014-02-12 超高純度なテトラヒドロカンナビノール−11−酸
JP2018178162A Pending JP2019031505A (ja) 2013-02-12 2018-09-22 超高純度なテトラヒドロカンナビノール−11−酸
JP2021133797A Pending JP2021185166A (ja) 2013-02-12 2021-08-19 超高純度なテトラヒドロカンナビノール−11−酸

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018178162A Pending JP2019031505A (ja) 2013-02-12 2018-09-22 超高純度なテトラヒドロカンナビノール−11−酸
JP2021133797A Pending JP2021185166A (ja) 2013-02-12 2021-08-19 超高純度なテトラヒドロカンナビノール−11−酸

Country Status (9)

Country Link
US (8) US20150141501A1 (enExample)
EP (2) EP3851101A1 (enExample)
JP (3) JP6689078B2 (enExample)
KR (2) KR20160002709A (enExample)
CN (2) CN110946854A (enExample)
AU (2) AU2014216440B2 (enExample)
BR (1) BR112015019180A8 (enExample)
CA (1) CA2900982C (enExample)
WO (1) WO2014127016A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160002709A (ko) 2013-02-12 2016-01-08 코버스 파마수티컬스, 아이엔씨. 초고순도 테트라하이드로카나비놀-11-오익산
AU2017258765A1 (en) * 2016-04-29 2018-11-29 Corbus Pharmaceuticals, Inc. Methods for the treatment of infection
RU2019103297A (ru) * 2016-07-11 2020-08-11 Интек Фарма Лтд. Гастроретентивные составы для перорального введения и пути их применения
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
US20210284621A1 (en) * 2018-05-31 2021-09-16 Corbus Pharmaceuticals, Inc. Cannabinoids and uses thereof
EP3864000A4 (en) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. CANNABIGEROL SYNTHESIS
US20200121614A1 (en) * 2018-10-18 2020-04-23 Bluegrass Farmacueticals, LLC Cannabinoid-infused transparent hydrogel skin patch
WO2020183456A1 (en) * 2019-03-10 2020-09-17 Bol Pharma Ltd. Cannabinoid combinations for treating chronic pain in dialysis patients
WO2021072325A1 (en) 2019-10-11 2021-04-15 Corbus Pharmaceuticals, Inc. Compositions of ajulemic acid and uses thereof
AR123027A1 (es) * 2020-07-21 2022-10-26 Np Pharma Holdings Llc Composiciones y métodos de cannabinoides para el tratamiento del dolor y la inflamación de las articulaciones

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US8586767B2 (en) 1999-03-22 2013-11-19 Craig Rick Travis Method for treatment of HIV and diseases of immune dysregulation
US6974835B2 (en) 2000-05-17 2005-12-13 Indevus Pharmaceuticals, Inc. Methods for decreasing cell proliferation based on (3r,4r)-Δ8-tetrahydrocannabinol-11-oic acids
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
EP1409473A2 (en) * 2001-03-07 2004-04-21 Websar Innovations Inc. CONVERSION OF CBD TO $g(D)?8 -THC AND $g(D)?9 -THC
EP1567513A2 (en) * 2002-12-04 2005-08-31 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical copositions
IL153277A0 (en) * 2002-12-04 2003-07-06 Pharmos Corp High enantiomeric purity dexanabinol for pharmaceutical compositions
AU2003297074A1 (en) 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
WO2004058251A1 (en) 2002-12-19 2004-07-15 University Of Massachusetts Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US20050070596A1 (en) 2003-05-12 2005-03-31 David Baker Methods for treatment of inflammatory diseases using CT-3 or analogs thereof
US20050009903A1 (en) * 2003-06-10 2005-01-13 Martin Billy R. CB2-selective cannabinoid analogues
KR20080000660A (ko) 2005-04-21 2008-01-02 오르펀 메디칼, 인크. 초순수 4-메틸피라졸의 제조 방법
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070037873A1 (en) 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
WO2007032962A2 (en) 2005-09-09 2007-03-22 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
US20070099988A1 (en) * 2005-10-31 2007-05-03 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
PT1903866E (pt) 2005-11-07 2016-06-09 Murty Pharmaceuticals Inc Distribuição melhorada de tetra-hidrocanabinol
US20080054300A1 (en) * 2006-06-30 2008-03-06 Philip Gene Nikkel Body contact structure and method for the reduction of drain lag and gate lag in field effect transistors
US8058227B2 (en) 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
US8044071B2 (en) 2007-10-18 2011-10-25 Abbott Laboratories Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist
WO2009158499A2 (en) 2008-06-25 2009-12-30 University Of North Texas Health Science Center At Fort Worth Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
WO2012048045A1 (en) 2010-10-05 2012-04-12 Jb Therapeutics, Inc. Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
US20120309820A1 (en) * 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
KR20160002709A (ko) 2013-02-12 2016-01-08 코버스 파마수티컬스, 아이엔씨. 초고순도 테트라하이드로카나비놀-11-오익산
US20150328198A1 (en) 2014-05-16 2015-11-19 The University Of North Carolina At Chapel Hill Methods of treating methicillin-resistant staphylococcus aureus (mrsa) using ppar-gamma agonists

Similar Documents

Publication Publication Date Title
Park et al. Resolving TRPV1-and TNF-α-mediated spinal cord synaptic plasticity and inflammatory pain with neuroprotectin D1
KR101546031B1 (ko) Cmt 및 관련 장애를 치료하기 위한 신규 치료적 접근법
Contarini et al. A co-ultramicronized palmitoylethanolamide/luteolin composite mitigates clinical score and disease-relevant molecular markers in a mouse model of experimental autoimmune encephalomyelitis
US20230277477A1 (en) Compositions for treating dermatological diseases
Dentesano et al. Inhibition of CD200R1 expression by C/EBP beta in reactive microglial cells
CN115252789A (zh) Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途
JP6175054B2 (ja) ヒストンアセチルトランスフェラーゼ活性剤の使用
Kim et al. Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs
Bennett et al. Immunomodulatory effects of Sceletium tortuosum (Trimesemine™) elucidated in vitro: Implications for chronic disease
Santoro et al. Effect of diazoxide on Friedreich ataxia models
Katsuki Nuclear receptors of NR1 and NR4 subfamilies in the regulation of microglial functions and pathology
de Souza et al. Intraarticular monomethyl fumarate as a perspective therapy for osteoarthritis by macrophage polarization
US20040037876A1 (en) Use or r-arylpropionic acids for producing medicaments for treating illnesses with a rheumatic nature
EP4157454A2 (en) Ppar-gamma activators, hdac inhibitors and their therapeutical usages
Sonvico et al. Drug delivery to the brain: how can nanoencapsulated statins be used in the clinic?
CN109350616B (zh) I-brd9或其衍生物在制备抗癫痫药物中的应用
Di Penta et al. A trifluoromethyl analogue of celecoxib exerts beneficial effects in neuroinflammation
WO2007054348A1 (de) Neue arzneimittel
JP6795580B2 (ja) 新規治療用化合物及びその治療における使用
JP6483627B2 (ja) 脳内アミロイドβ蓄積症の予防または治療剤
TW201038265A (en) Agent for treatment of cognitive impairment
RS67696B1 (sr) Vafidemstat za lečenje neagresivnih simptoma graničnog poremećaja ličnosti
JP2008508208A (ja) 炎症性疾患の治療におけるrxrアンタゴニスト
US11497723B1 (en) PPAR-gamma activators, HDAC inhibitors and their therapeutical usages
EP3390347A1 (en) Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders